Paper
0
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Authors
Nicolino Ruperto,Hermine Brunner
Pierre Quartier,Tamás Constantin,Nico Wulffraat,Gerd Horneff,Riva Brik,Liza McCann,Özgür Kasapçopur,Lidia Rutkowska‐Sak,Rayfel Schneider,Yackov Berkun,Inmaculada Calvo,Müferet Ergüven,Laurence Goffin,Michaël Hofer,Tilmann Kallinich,Sheila Oliveira,Yosef Uziel,Stefania Viola,Kiran Nistala,Carine Wouters,Rolando Cimaz,M Ferrandiz,Berit Flatø,María Gámir,Isabelle Koné‐Paut,Alexei Grom,Bo Magnusson,Seza Özen,Flávio Sztajnbok,K. Lheritier,Kenneth Abrams,Dennis Kim,Alberto Martini,Daniel Lovell
+34 authors
,Ken AbramsPublished
Dec 20, 2012
Show more
Save
Tip0
TipSave
Abstract
Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti–interleukin-1β monoclonal antibody, in two trials.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.